Appropriate use criteria for dementia amyloid imaging in Switzerland – mini-review and statement on behalf of the Swiss Society of Nuclear Medicine and the Swiss Memory Clinics

Abstract

While FDG-PET imaging of the brain for the differential diagnosis of dementia has been covered by the compulsory health insurance in Switzerland for more than a decade, beta-amyloid-PET just recently has been added to the catalogue of procedures that have been cleared for routine use, provided that a set of appropriate use criteria (AUC) be followed. To provide guidance to dementia care practitioners, the Swiss Society of Nuclear Medicine and the Swiss Memory Clinics jointly report a mini-review on beta-amyloid-PET and discuss the AUC set into effect by the Swiss Federal Office of Public Health, as well as their application and limitations.

Zusammenfassung

Die Beta-Amyloid-PET-Bildgebung des Gehirns ist mit der Zulassung für die klinische Routineanwendung durch Swissmedic von 3 EU-weit bereits länger kommerziell verfügbaren Amyloid-β-PET-Radiopharmaka nun auch in dem Nicht-EU-Land Schweiz allgemein verfügbar geworden. Seit dem 01.04.2020 unterliegt die Anwendung von Beta-Amyloid-PET der gesetzlichen Leistungspflicht durch die obligatorische Schweizer Krankenversicherung für die Differenzialdiagnose demenzieller Erkrankungen unter bestimmten Voraussetzungen.

Im Namen der Schweizer Gesellschaft für Nuklearmedizin (SGNM) und der Schweizer Memory-Kliniken publiziert die AG Neuronuklearmedizin der SGNM die aktuell gültigen Anwendungskriterien im Rahmen der gesetzlichen Leistungspflicht in der Schweiz, um sowohl den verordnenden Demenzspezialisten, Gerontopsychiatern und Neurologen, als auch den durchführenden Nuklearmedizinern Handlungsempfehlung an die Hand zu geben und einen aktuellen Kurzüberblick über Möglichkeiten und Grenzen der Beta-Amyloid-Bildgebung im klinischen Alltagskontext zu geben.

Key words

beta-amyloid-imaging - dementia - beta-amyloid-pet - appropriate use criteria

Schlüsselwörter

Beta-Amyloid-Bildgebung - Demenz - Beta-Amyloid-PET - Leitlinien

Publication History

Received: 30 June 2020

Accepted: 01 October 2020

Article published online:
20 October 2020

• References

• 1 Klunk WE, Engler H, Nordberg A. et al Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound‐B. Ann Neurol 2004; 55: 306-319 . Available at: http://onlinelibrary.wiley.com/doi/10.1002/ana.20009/full
• 2 Mueller SG, Weiner MW, Thal LJ. et al Ways toward an early diagnosis in Alzheimer’s disease: the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Alzheimers Dement 2005; 1: 55-66 . doi:10.1016/j.jalz.2005.06.003
• 3 Johnson KA, Minoshima S, Bohnen NI. et al Appropriate Use Criteria for Amyloid PET: A Report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. J Nucl Med 2013; 54: 476-490 . doi:10.2967/jnumed.113.120618
• 4 Bürge M, Bieri G, Brühlmeier M. et al Die Empfehlungen der Swiss Memory Clinics für die Diagnostik der Demenzerkrankungen Recommendations of Swiss Memory Clinics for the Diagnosis of Dementia. Praxis (Bern 1994) 2018; 107: 435-451 . Available at: https://doi.org/10.1026/a002948 [Accessed 2018 April 17]
• 5 Eidgenössisches Departement des Innern. Verordnung des EDI über Leistungen in der obligatorischen Krankenpflegeversicherung (Krankenpflege-Leistungsverordnung, KLV), Änderung vom 7. Februar 2020. Switzerland: 2020 https://www.admin.ch/opc/de/official-compilation/2020/519.pdf
• 6 Allegri RF, Chrem Méndez P, Calandri I. et al Prognostic value of ATN Alzheimer biomarkers: 60‐month follow‐up results from the Argentine Alzheimer’s Disease Neuroimaging Initiative. Alzheimer’s Dement Diagnosis, Assess Dis Monit 2020; 12: e12026 . doi:10.1002/dad2.12026
• 7 Shi Z, Fu LP, Zhang N. et al Amyloid PET in Dementia Syndromes: A Chinese Multicenter Study. J Nucl Med 2020; DOI: 10.2967/jnumed.119.240325.
• 8 Teipel SJ, Dyrba M, Chiesa PA. et al In vivo staging of regional amyloid deposition predicts functional conversion in the preclinical and prodromal phases of Alzheimer’s disease. Neurobiol Aging 2020; DOI: 10.1016/j.neurobiolaging.2020.03.011.
• 9 Meyer PF, McSweeney M, Gonneaud J. et al AD molecular: PET amyloid imaging across the Alzheimer’s disease spectrum: From disease mechanisms to prevention. Prog Mol Biol Transl Sci 2019; 165: 63-106 . doi:10.1016/bs.pmbts.2019.05.001
• 10 Rabinovici GD, Gatsonis C, Apgar C. et al Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA 2019; 321: 1286-1294 . doi:10.1001/jama.2019.2000
• 11 Barthel H, Sabri O. Clinical Use and Utility of Amyloid Imaging. J Nucl Med 2017; 58: 1711-1717 . doi:10.2967/jnumed.116.185017
• 12 Chiotis K, Saint-Aubert L, Boccardi M. et al Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase development framework. Neurobiol Aging 2017; 52: 214-227 . doi:10.1016/J.NEUROBIOLAGING.2016.07.012
• 13 Bernhard M, Bern B. Policies on Ageing and Health: A selection of innovative models. Multisector Action for a life course Approach to Healthy Ageing. 2016 Available at (Accessed 2020 June 8): http://www.alter-migration.ch/fileadmin/templates/pdf/ONLINE_HEALTHY_AGEING_191216.pdf
• 14 de Wilde A, van der Flier WM, Pelkmans W. et al Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort. JAMA Neurol 2018; DOI: 10.1001/jamaneurol.2018.1346.
• 15 de Wilde A, Ossenkoppele R, Pelkmans W. et al Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project. Alzheimer’s Dement 2019; 15: 1458-1467 . doi:10.1016/j.jalz.2019.07.003
• 16 Apostolova LG, Haider JM, Goukasian N. et al Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care. Alzheimer’s Dement Diagnosis, Assess Dis Monit 2016; 5: 15-22 . doi:10.1016/j.dadm.2016.12.001
• 17 Boccardi M, Nicolosi V, Festari C. et al Italian consensus recommendations for a biomarker-based aetiological diagnosis in mild cognitive impairment patients. Eur J Neurol 2020; 27: 475-483 . doi:10.1111/ene.14117
• 18 Sabbagh MN, Lue LF, Fayard D. et al Increasing Precision of Clinical Diagnosis of Alzheimer’s Disease Using a Combined Algorithm Incorporating Clinical and Novel Biomarker Data. Neurol Ther 2017; 6: 83-95 . doi:10.1007/s40120-017-0069-5